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Abstract
Background: Breast-conserving treatment of invasive breast carcinoma with an extensive
intraductal component (EIC) is associated with DCIS-involved surgical margins and therefore it has
an increased recurrence rate. EIC is a non-palpable lesion of which the size is frequently
underestimated on mammography. This study was undertaken to evaluate the accuracy of MRI in
size assessment of breast cancer with EIC.
Methods: 23 patients were identified and the mammographic (n = 21) and MR (n = 23) images
were re-reviewed by a senior radiologist. Size on MR images was compared with histopathological
tumour extent.
Results: The correlation of radiological size with histopathological size was r = 0.20 in
mammography (p = 0.39) compared to r = 0.65 in MRI (p < 0.01). Mammography underestimated
histopathological tumour size in 62%. MR images over- or underestimated tumour size in 22% and
30% of the cases, respectively. In poorly differentiated EIC, MRI adequately estimated the extent
more often compared to moderately differentiated EIC (60% versus 25%, respectively).
Conclusion: Size assessment of MRI imaging was more accurate compared to mammography. This
was predominantly true for poorly differentiated EIC.
Background
Breast-conserving surgery has become a standard therapy
for early-staged, resectable breast carcinomas [1]. An
important factor in achieving local tumour control and
patient survival is the adequacy of the excision. Patients
with tumour-involved surgical margins have lower overall
survival rates compared to patients with completely
excised breast cancers [2-4].
It has been shown that breast-conserving treatment of
breast cancer with an extensive intraductal component
(EIC) gives rise to a higher recurrence rate which is most
likely due to the presence of residual ductal carcinoma in
situ (DCIS) [5-7]. Holland and colleagues have shown
that primary breast tumours with EIC were more likely to
have residual DCIS anywhere in the remaining breast
compared to invasive breast cancers without an EIC [8].
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EIC is found in 30%–40% of all invasive breast carcino-
mas [7-9]. Additionally, EIC is non-palpable which makes
a microscopically complete resection technically difficult.
This makes an accurate preoperative measurement of
invasive breast cancer with surrounding DCIS mandatory
in order to decrease the need of secondary interventions
caused by tumour-involved surgical margins. Even though
DCIS is visible on a mammography, its histological size is
frequently underestimated [8,9].
For invasive breast carcinoma, magnetic resonance imag-
ing (MRI) has been shown to accurately predict tumour
size and multifocality with high sensitivity [10-15].
The current study was undertaken to evaluate whether the
size of breast carcinomas with EIC can be accurately meas-
ured on MRI images.
Methods
We selected 23 female patients from the database of the
Pathology department with a histopathologically con-
firmed diagnosis of an invasive breast carcinoma and a
DCIS component who underwent a MRI breast examina-
tion in the period between January 2000 and December
2004. During this period, MRI was randomly performed
and no specific criteria were used whether patients under-
went a MRI or not. During the study period, performance
of MR breast imaging was not standard care. Currently
though, MRI is routinely used as standard work-up for
breast malignancies in our institute.
As in this retrospective study patient care has been evalu-
ated, no ethical approval was necessary according to our
local policy. Similarly, no informed consent was
obtained.
Patients with DCIS and a micro-invasive carcinoma (size
of invasive carcinoma of 1 mm or less) were also consid-
ered eligible.
Tumours were considered EIC positive when DCIS was
predominant lesion and when DCIS was clearly extending
beyond the infiltrating carcinoma, according to the defini-
tion of Holland and colleagues [8].
The medical records, mammographic and MR images of
all 23 patients were retrospectively reviewed and all avail-
able clinical, radiological, and pathological data were col-
lected. Items noted were tumour diagnosis, location of the
lesion, preoperative histopathological diagnosis, number
of surgical procedures, definitive surgical treatment, his-
topathological grading of in situ and invasive carcinoma,
and the percentage of EIC of the entire lesion.
A senior radiologist (C.B.) experienced in reading breast
images (approximately 1500 MR breast images per year)
reviewed both mammography and MRI images without
knowledge of the histopathological findings.
Mammographic examination (Senographe 2000, GE
Medical systems) constituted of standard oblique and
craniocaudal projections. Images were reviewed for pres-
ence of abnormalities by microcalcifications, masses, or
architectural distortions.
MR images were made at field strength of 1.5 Tesla (Sym-
phony, Siemens) with the patient placed in a prone posi-
tion with the breasts hanging in a double-breast coil.
The scanning protocol consisted of 1 pre-contrast FLASH
3D acquisitions at a high spatial resolution (TR/TE 7.8/4,
FA 20, rectangular FOV 340, matrix 256*256, slice thick-
ness 1.3, orientation coronal, AT 90s). Thereafter, the
FLASH 3D sequence was repeated 5 times after intrave-
nous administration of contrast agent (0.2 mmol gadolin-
ium per kilogram of body weight). Subsequently
subtraction images were created from the pre-contrast and
the second post-contrast acquisition.
The subtracted FLASH 3D images were viewed on a
Dynacad working station (InVivo) and used for evalua-
tion of both morphological and dynamic imaging param-
eters. Morphological pattern of lesions was classified as
round or oval, irregular or ductal whereas enhancement
was noted as heterogeneous or homogeneous. Margins
were categorised as regular, irregular or spiculated. Kinetic
contrast-enhancement characteristics over time were clas-
sified as progressive, plateau, or washout. Criteria for sus-
picious enhancement during time were defined as a signal
increase followed by a plateau or washout phase.
The results of both mammography and MRI were scored
according to the Breast Imaging Reporting and Data Sys-
tem (BI-RADS) classification [16]. Categories were: cate-
gory 1, negative; category 2, benign finding; category 3,
probably benign finding, follow-up requested; category 4,
suspicious abnormality, and category 5, highly suggestive
of malignancy.
Histopathological examination and sampling of the exci-
sional biopsy specimens were based on specimen X-rays
of the whole and sliced specimens. Handling of the mas-
tectomy specimens was based on the correlated radio-
graphic and pathologic technique developed by Egan,
which has been routinely performed in our pathology
department for many years [17]. This method is described
in detail elsewhere [18]. The specimens were cooled and
sliced in serial sections with approximately 5-mm inter-
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vals. Radiographs were made from the tissue slices. Suspi-
cious lesions and randomly selected areas from each
quadrant and the nipple were sampled.
The histopathological extent of the tumour was measured
as the total diameter of the intraductal component in
which the invasive carcinomas were located. For those
patients who underwent a re-excision, the extent of the
tumour within the re-excised specimen was recorded and
added to the tumour size of the first excision. The total
tumour size therefore included both the in situ and the
invasive component.
Lesion sizes as measured by the different methods were
categorized in groups by 5 mm (0–5 mm, 6–10 mm, etc).
A difference of 10 mm or less between size assessed on
imaging and size at histopathological examination is con-
sidered as an adequate measurement. The Spearman cor-
relation coefficient was calculated to analyse the size
assessment at mammography, MRI, and histopathologi-
cal examination.
The data were analysed with SPSS version 11.5 (SPSS, Chi-
cago, IL, USA). For all statistical analyses a p-value of <
0.05 was considered statistically significant.
Results
Table 1 lists patient and tumor characteristics of the study
population. The median age at diagnosis was 51 years
(range: 28–68 years). Final treatment constituted of a
mastectomy in the majority of patients (91%). After defin-
itive treatment, surgical margins were free of tumour in 22
patients whereas in one patient the surgical margin was
focally involved.
Preoperative mammographic examination was performed
in all but two patients whereas all 23 patients underwent
MR breast imaging.
Table 1: Patient and tumor characteristics of the study population (n = 23).
Characteristic Category N %
Tumour diagnosis Clinical symptoms 5 22
Mammography 16 70
MRI 2 8
Location of the tumour Inner quadrant 2 9
Outer quadrant 17 74
Central 4 17
Preoperative diagnosis of histological core needle biopsy DCIS 5 21
DCIS with invasive carcinoma 14 61
Not conclusive 2 9
Not performed 2 9
Number of surgical procedures 1 17 74
2 5 22
3 1 4
Final treatment Breast-conserving surgery 2 9
Mastectomy 21 91
Axillairy staging Sentinel lymph node biopsy 10 44
Axillairy lymph node dissection 10 44
Sentinel lymph node biopsy followed by axillairy
lymph node dissection 3 13
Grading of DCIS Grade I, well differentiated 0 0
Grade II, moderately differentiated 8 35
Grade III, poorly differentiated 15 65
Grading of invasive carcinoma Grade I, well differentiated 8 35
Grade II, moderately differentiated 6 26
Grade III, poorly differentiated 9 39
Size of invasive carcinoma ≤ 1 mm 4 17
1–10 mm 8 35
11–20 mm 4 17
21–30 mm 5 22
31–40 mm 1 4
41–50 mm 1 4
Percentage EIC <50% 5 22
50%–75% 6 26
>75% 12 52
DCIS: ductal carcinoma in situ; EIC extensive intraductal component
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Mammographic images revealed abnormalities (defined
as a BI-RADS classification 4 or 5) in 17/21 examinations
(81%). On two mammograms (10%), no abnormalities
were seen and findings on mammographic exams of
another two patients were classified as 'probably benign'
(one patient with microcalcifications and one patient
with a density). These last four exams (19%) are thus con-
sidered as false-negative findings. The predominant mam-
mographic findings were microcalcifications with or
without a density or an architectural distortion (62%).
The specific findings on MRI are listed in detail in table 2.
An example of a MR image is presented in figure 1.
In two patients, MR images were available on plain films
only. In these patients, therefore, no data on contrast
enhancement kinetics are presented. All MR exams
showed abnormalities which after reviewing were classi-
fied as either 'suspicious' or 'highly suggestive of malig-
nancy' according to the BI-RADS classification (score 4
and 5, respectively). Margins of the lesions on MRI were
irregular or spiculated in the majority of tumours (87%).
Histopathological examination of the excised breast spec-
imen revealed both invasive and in situ breast carcinoma
in all patients. The majority of tumours were composed of
an area with in situ carcinoma in which an invasive carci-
noma was located. In four tumours (17%), the size of the
invasive carcinoma was 1 mm or less and these lesions
were considered as micro-invasive carcinomas.
In two cases, the invasive tumour and DCIS were adja-
cently located and for these lesions, the total tumour size
was calculated as the sum of DCIS size and invasive
tumour size. In another three patients, the tumour size
was calculated by adding the size of re-excised residual
tumour to the size of the initial excised lesion.
Mean whole tumour size for the study population was 49
mm (median 45 mm, range: 18–105 mm). The EIC
accounted for 50% or more of the complete tumour size
in 18 patients (table 1).
Table 3 and figure 2 present the results of size assessment
by mammography and MRI compared to the histopatho-
logical size measurements. These results are expressed as
underestimation, adequate measurement, or overestima-
tion of the histopathological size.
An adequate measurement, defined as a difference
between histopathological size and radiological size of 10
mm or less, was found in six mammographic exams
(28%) compared to 11 MRI exams (48%). The correlation
of mammographic tumour size with histopathological
size was r = 0.20 (p = 0.39). For MRI size assessment, the
correlation with histopathological tumour size was r =
0.65 (p < 0.01).
Mammography underestimated histopathological
tumour size in the majority of cases (13, 62%). In con-
trast, MR imaging was equally like to over- or underesti-
mate estimate tumour size: in five and seven patients,
respectively. Of tumours surrounded by poorly differenti-
ated DCIS, MRI size assessment was adequate in 60% (9/
15) compared to 25% (2/8) in moderately differentiated
DCIS. In the moderately differentiated EIC, MRI underes-
timated tumour size in half of cases (4/8) compared to
20% (3/15) in poorly differentiated EIC (p = 0.23).
Table 2: MRI findings of the study population (n = 23).
Characteristic Category N %
Morphologic pattern Round or oval 2 9
Lobulated 2 9
Irregular 4 17
Ductal 7 30
Segmental 8 35
Enhancement Heterogeneous 23 100
Homogeneous 0 0
Margins Regular 3 13
Irregular 11 48
Spiculated 9 39
Kinetic contrast enhancement Progressive 7 30
Plateau 1 4
Washout 13 57
Unknown1 2 9
BI-RADS classification 4: suspicious abnormality 9 39
5: highly suggestive of malignancy 14 61
1 MR images of 2 patients were reviewed on a plain film MRI on which no kinetic contrast enhancement could be assessed.
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Discussion
As breast conservation and prevention of recurrent disease
are the main goals in treatment of early resectable breast
cancer and as presence of an EIC is a risk factor for recur-
rent disease, it is important to reliably identify the tumour
extent preoperatively.
This retrospective analysis on size assessment of invasive
carcinoma with EIC revealed that this type of breast
tumours can be visualised on MRI and we found a signif-
icant correlation between tumour extent on MRI and the
size measured at histopathological examination. Overall,
size assessment on MRI was more accurately when com-
pared to mammography. Mammographic determination
of the extent of DCIS and, therefore, EIC mainly depends
on the presence of microcalcifications [9,19,20] However,
mammographic estimates, based on the extent of micro-
calcifications, frequently underestimates tumour size
[8,9] Additionally, mammography does not reliably dem-
onstrate the extent of uncalcified DCIS which is supported
by the findings of the current analysis.
Enhancement of malignant tumours on MRI is caused by
the presence of tumor-induced angiogenesis. An increased
density of microvessels will increase blood flow, which
causes contrast enhancement. Furthermore, tumor-
induced microvessels demonstrate structural abnormali-
ties which give rise to leakage of contrast medium. This
causes the characteristic malignant contrast-enhancement
kinetics (plateau and washout phenomenon) [21-23].
An increased amount of stromal microvessels has been
shown for DCIS [21]. Gilles et al. showed contrast
enhancement in DCIS lesions and micro-invasive carcino-
mas and subsequently demonstrated tumor angiogenesis
in enhancing lesions [23].
This makes MR breast imaging able to detect both calci-
fied and uncalcified DCIS [15,24,25].
And, therefore, invasive breast cancer with EIC can be vis-
ualised on MR breast imaging. Reported detection rates of
MRI for invasive cancer with EIC differs between 45%–
100% (table 4) [12,25-34].
The morphologic pattern of lesions on MRI were ductal or
segmental in 15/23 (65%) lesions, whereas margin
enhancement on MRI was irregular of spiculated in 20/23
(87%) tumours. This probably reflects the extension of
DCIS and has been reported by others as well [12,25,29,
30,34].
Data on size assessment of breast carcinomas with EIC are
scarce. Correlation coefficients between MRI tumour size
and histopathological extent reported differ between r =
0.42 and r = 0.87 [28,30,34]. This is in concordance with
results of the presented study (r = 0.65).
In the presented study population however, the size of
EIC was underestimated on MRI in 30% (7/23). There
also was a trend towards more underestimation of moder-
ately differentiated EIC compared to poorly differentiated
EIC on MRI, though this reached no statistical signifi-
cance. This has also been found by others: in the series of
Goethem et al. five out of 12 low grade EIC (42%) were
not depicted in MRI compared to 11 out of 38 high grade
EIC tumours (28%) [34].
These false-negative findings could be explained by
microvessel density: in the previously mentioned study of
Gilles and colleagues the two false-negative cases were
found to exhibit weak tumor angiogenesis in the stroma
around the ducts involved by DCIS [23]. Similarly, it has
been shown that high grade DCIS (i.e. poorly differenti-
ated tumours) has an higher microvessel density when
compared to non-high grade lesions [21,22].
MR image demonstrating an inhomogeneous spiculated mass of 30 mm within the left breast.Figure 1
MR image demonstrating an inhomogeneous spicu-
lated mass of 30 mm within the left breast. At his-
topathological examination a 85 mm moderately 
differentiated invasive ductal carcinoma with surrounding 
moderately differentiated DCIS was found.
Table 3: Size assessment of invasive breast carcinoma with an 
extensive DCIS component by mammography (n = 21) and MRI 
(n = 23) compared to histopathological size.
Radiological size assessment Mammography
N (%)
MRI
N (%)
Underestimation > 50 mm 4 (19) 3 (13)
30–49 mm 1 (5) 1 (4)
20–29 mm 4 (19) 1 (4)
11–19 mm 4 (19) 2 (9)
Adequate measurement* 6 (28) 11 (48)
Overestimation 11–20 mm 1 (5) 3 (13)
21–30 mm 1 (5) 2 (9)
* A difference of 10 mm or less between size assessed on imaging and 
size at histopathological examination is considered as an adequate 
measurement.
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Size overestimation of DCIS and EIC by MRI has been
described previously [15,24,28,34,35]. In the presented
population, MRI overestimated approximately 20 per cent
of EIC tumours. Overestimation of tumour extent is in the
majority of cases due to false-positive enhancement of
benign proliferative processes such as fibrocystic changes
or adenosis [12,15,23,25,35].
The most important clinical issue however is whether MRI
has in beneficial effect on outcome of treatment. In the
study of Berg and colleagues, only MRI depicted DCIS in
6 out of 19 breasts with EIC positive carcinomas, whereas
in five of these breast conserving surgery was initially
anticipated [15].
Recently, the relation between preoperative MRI and out-
come after breast-conserving treatment for early stage (T1
or T2) and in situ breast carcinoma was determined in a
large non-randomised cohort study [36]. It was concluded
that the use of MRI was not associated with an improved
outcome after breast-conserving treatment.
Conclusion
This report shows that invasive breast cancer with EIC can
be visualised on MRI. In contrast to mammography,
tumour extent measured on MRI correlates significantly
with histopathological tumour size, but, tumour size is
underestimated frequently, which was most obviously
seen in poorly differentiated EIC. This study has some
Scatter diagram and the correlation of diameter on radiology (x-axis) with histopathological size assessment (y-axis)Figure 2
Scatter diagram and the correlation of diameter on radiology (x-axis) with histopathological size assessment 
(y-axis)
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limitations to be addressed. It is a retrospective review of
non-consecutive patients with a proven diagnosis of an
EIC breast carcinoma. The number of patients is relatively
small, which makes firm statistical conclusions difficult.
Therefore, future research is mandatory to explore the
value of MRI in breast cancer with EIC. The most impor-
tant issue to address is whether MRI is able to improve
outcome by decreasing the need for re-operations and
lowering recurrence rates.
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